It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).
It is very uncertain whether inhaled corticosteroids changes need for nasal continuous positive airway pressure compared with no treatment or placebo (very low certainty).
It is very uncertain whether inhaled corticosteroids changes need for mechanical ventilation compared with no treatment or placebo (very low certainty).
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).